Skip to main content

Table 1 Demographic and Cancer Treatment-Related Characteristics (N = 220)

From: Exploring the efficacy of an electronic symptom assessment and self-care intervention to preserve physical function in individuals receiving neurotoxic chemotherapy

Variable

Intervention

(N = 108)

Control

(N = 112)

p value

Age at Baseline

  

p = 0.33

 Median (Range)

54 (26–86)

56 (22–87)

 

Time on Study (Days)

  

p = 0.64

 Median (Range)

122 (49–482)

113 (49–378)

 

Gender

  

p = 0.89

 Male

51 (47%)

51 (46%)

 

 Female

57 (53%)

61 (54%)

 

Ethnicity/Race

  

p = 0.95

 Caucasian

94 (87%)

98 (87%)

 

 Minority

4 (4%)

3 (3%)

 

 Missing

10 (9%)

11 (10%)

 

Working Status

  

p = 0.49

 Working

72 (67%)

79 (71%)

 

 Not working

29 (27%)

23 (20%)

 

 Missing

7 (6%)

10 (9%)

 

Clinical Service

  

p = 0.83

 Medical Oncology

95 (88%)

100 (89%)

 

 Radiation Oncology

13 (12%)

12 (11%)

 

Cancer Diagnosisa

  

p = 0.83

 Breast

34 (31%)

42 (38%)

 

 Head and Neck

17 (16%)

14 (12%)

 

 Colorectal

16 (15%)

14 (12%)

 

 Prostate

12 (11%)

10 (9%)

 

 Esophageal

7 (6%)

3 (3%)

 

 Testicular

7 (6%)

5 (4%)

 

 Gastrointestinal Other

4 (4%)

2 (2%)

 

 Other

4 (4%)

3 (3%)

 

 Sarcoma

3 (3%)

0

 

 Bladder

2 (2%)

9 (8%)

 

 Gastric

2 (2%)

5 (4%)

 

 Pancreatic

0

1 (1%)

 

 Unknown Primary

0

4 (4%)

 

Stage

  

p = 0.29

 I

14 (13%)

19 (16%)

 

 II

30 (28%)

29 (26%)

 

 III

30 (28%)

22 (20%)

 

 IV

30 (28%)

40 (36%)

 

 Missing

4 (4%)

2 (2%)

 

Chemotherapy Type

  

p = 0.98

 Taxane Only

62 (58%)

62 (55%)

 

 Platinum Only

39 (36%)

42 (38%)

 

 Platinum and Taxane

7 (6%)

8 (7%)

 

Cumulative Dose Categoryb

  

p = 0.31

 Low Dosec

25 (23%)

26 (23%)

 

 Moderate Dosed

35 (32%)

48 (43%)

 

 High Dosee

47 (44%)

37 (33%)

 

 Missing

1 (1%)

1 (%)

 

Neurotoxic Chemotherapy Dose Reduction

  

p = 0.60

 None

96 (89%)

104 (93%)

 

 Neuropathy-Related

9 (8%)

6 (5%)

 

 Other Symptom-Relatedf

3 (3%)

2 (2%)

 
  1. This table describes the demographic characteristics of the patients at baseline
  2. aTo compare distribution of cancer diagnosis for intervention versus control, the diagnoses with < 10 observations are grouped together into another category (i.e., esophageal, testicular, gastrointestinal, miscellaneous, sarcoma, bladder, gastric, pancreatic and unknown primary)
  3. bFor participants receiving multiple neurotoxic chemotherapy agents, dose category was determined based on the highest dose of one of the specific agents they were receiving
  4. cPaclitaxel < 700 mg/m2; Oxaliplatin < 800 mg/m2; Docetaxel < 300 mg/m2; Cisplatin < 300 mg/m2
  5. dPaclitaxel 700–1400 mg/m2; Oxaliplatin 800–1000 mg/m2; Docetaxel 300–600 mg/m2; Cisplatin 300–600 mg/m2
  6. ePaclitaxel > 1400 mg/m2; Oxaliplatin > 1000 mg/m2; Docetaxel > 600 mg/m2; Cisplatin > 600 mg/m2
  7. fNeurotoxic chemotherapy dose reduction due to other symptom-related causes included fatigue, pain, skin changes, bowel problems, or breathing problems